Patients treated with prostacyclin or prostacyclin analogs (PCA) for more advanced PAH had 5-fold higher NTproBNP plasma concentrations (389.6 ± 62.0 ng/L vs. 78.0 ± 11.5 ng/L; p < 0.0001; Figure S2) and 2-fold higher sRAGE plasma levels versus controls (3481 ± 291.3 pg/mL vs. 1766 ± 121.9 pg/mL; p < 0.0001; Figure S2). The gene discussed is NPPB; the disease is pulmonary arterial hypertension.